Pfizer is expanding its recall of anti-smoking drug Chantix after testing found high levels of carcinogenic material in the pill. The leading prescription for smoking secession, Chantix is prescribed to over half a million people each year and accounts for $1.1 BILLION in revenue for Pfizer each year.
While commercial cigarettes are undoubtedly unhealthy, the market for pharmaceutical cessation products is enormous. So is the money spent on advertising. Pfizer spends over $200 million a year to promote the drug (which is over 400% more expensive than it was in 2008).